Innovation Prize 2014 Finalist iTeos concludes a deal with Pfizer

Innovation Prize 2014 Finalist iTeos concludes a deal with Pfizer

We are proud to announce that one of the 5 finalists of the Innovation Prize 2014 has concluded a deal of $ 25 million with the pharmaceutical company, Pfizer.

This Belgian society, iTeos Therapeutics lead by Michel Detheux, develops Indoleamine 2,3 Dioxygenase(IDO1) and Tryptophan – 2,3-Dioxygenase (TDO2) drug candidates.

This news highlights the quality of the projects submitted during the Innovation Prize and recognizes the high performance and expertise of our Innovation Prize Jury members.

Don’t hesitate to contact us for more information on our candidates and on the Innovation Prize 2015.

Rafi Mardachti, CEO

You can download the Innovation Prize 2015 Brochure by filling the form below :

[email-download download_id=”2476″ contact_form_id=”2484″]


Comments are closed.